Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.

ABSTRACT:

Context

The first year after transplantation is characterized by rapid bone loss.

Objective

The aim of this study was to compare zoledronic acid (zoledronate) and alendronate for prevention of transplantation bone loss.

Design and setting

A randomized clinical trial was conducted at a transplantation center.

Patients

The study included 84 adults undergoing heart or liver transplantation and a concurrently transplanted, nonrandomized reference group of 27 adults with T scores greater than -1.5.

Interventions

Alendronate (70 mg weekly for 12 months) or one 5-mg infusion of zoledronate were both initiated 26 ± 8 d after transplantation.

Main outcome measures

The primary outcome was total hip bone mineral density (BMD) 1 yr after transplantation. Seco

SUBMITTER: Shane E 

PROVIDER: S-EPMC3591679 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature